Why do some biotech startups change the world, while others burn through millions and fail?In this episode of The HumanWare Project, Patrick Aisher, chairman of Kinled and recognised by the Financial Times as one of Europe’s leading health-tech investors, shares the hard-earned lessons from decades of backing medtech and biotech companies.Patrick reflects on early wins, including a the success of a drug discovery startup later licensed to AstraZeneca, and contrasts them with the harsh reality that most biotech ventures are high-risk and slow to succeed. His core advice: Be ambitious enough to reach for breakthroughs, but realistic enough to know when a project is only a marginal improvement.For entrepreneurs, this is a candid guide on how investors judge your startup. For investors, it’s a sober look at what separates true innovation from failure.Subscribe to The HumanWare Project for more guided explorations into health, presence, and human potential.

Ver todos los episodios